Fairvalue-Calculator Fairvalue-Calculator
EN DE

Enwei Pharmaceutical Co (301331) Fair Value & Analysis

Healthcare · CN · Market cap 2.2B CNY

Price¥24.53
Fair Value¥11.25
Upside-54.1%
Quality95/100
Evidence: High Range ¥8.93 – ¥13.88

Fair value as of: Jun 24, 2026

Analysis

Enwei Pharmaceutical Co (301331) currently trades at ¥24.53, while our model-based Fair Value estimate is ¥11.25 — implying the stock looks roughly 54.1% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Enwei Pharmaceutical Co., Ltd. engages in the development and sale of Chinese medicines in China. The company offers drugs in the areas of gynecology, pediatrics, and respiratory system fields. The company was founded in 2005 and is based in Chengdu, China.

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +1949% Jiangsu Hengrui Pharmaceuticals Co (600276) -46% Sun Pharmaceutical Industries Limited (SUNPHARMA) -44% Zoetis Inc (Z1TS34) -74% Hansoh Pharmaceutical Group (3692) -47% Divi's Laboratories Limited (DIVISLAB) -70%

Frequently asked questions

Is Enwei Pharmaceutical Co (301331) undervalued?
As of Jun 24, 2026, our model estimates a fair value of ¥11.25 versus a price of ¥24.53 — about −54% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 301331?
Our 21-model fair value for Enwei Pharmaceutical Co is ¥11.25 (as of Jun 24, 2026), built from audited fundamentals. The current price is ¥24.53.
What is the quality score of 301331?
Enwei Pharmaceutical Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.